ACTRN12609000278235撤回4 期
A randomised, double-blind, placebo-controlled trial to determine the effect of zoledronate on endothelial dysfunction in osteoporotic elderly patients who have suffered a hip fracture
A/Prof. Gustavo Duque0 个研究点目标入组 60 人开始时间: 2009年5月15日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 撤回
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 65 Years 至 100 Years（—）
- 性别
- All
入选标准
- •1- Diagnosis of osteoporosis based on bone mineral density (BMD)
- •2- Previous history of hip fracture a year prior to the administration of the dose
排除标准
- •1)creatinine clearance < 35 ml/min
- •2)pre-existing hypocalcemia must be treated by adequate intake of calcium and vitamin D before therapy with zoledronic acid
- •3)active history of uveitis, iritis, or episcleritis
- •4)metastatic cancer or cancer diagnosed less than 2 years ago where treatment is still ongoing
- •5)History of diabetes mellitus
- •6)Active primary hyperparathyroidism
- •7)Hypothyroidism, not appropriately controlled with long-term thyroxine therapy
- •8)Serum 25-hydroxyvitamin D concentrations <15 ng/
研究者
相似试验
进行中（未招募）
不适用
A study to evaluate the potency, quality of life, side effects and tolerability of long-term treatment (24 weeks) with prucalopride in patients aged =18 years with chronic constipation.Chronic constipationMedDRA version: 14.1Level: PTClassification code 10010774Term: ConstipationSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2011-000670-62-HUShire-Movetis NV360
尚未招募
不适用
A randomised control trial of the effect of Niacinamide on Fibroblast Growth factor 23 (FGF23) levels in Chronic Kidney Disease.ACTRN12613001229763Christopher Hood90
已完成
不适用
The efficacy of treatment with St John?s Wort for premenstrual syndrome (PMS)Pre-menstrual syndrome (PMS)Urological and Genital DiseasesPain and other conditions associated with female genital organs and menstrual cycleISRCTN31487459niversity of Leeds (UK)41
已完成
3 期
IMPROVE: IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney DiseasePhosphate imbalance (as a risk factor for cardiovascular disease) in patients with Chronic Kidney DiseaseRenal and Urogenital - Kidney diseaseCardiovascular - Diseases of the vasculature and circulation including the lymphatic systemACTRN12610000650099Australasian Kidney Trials Network (University of Qld)278
进行中（未招募）
1 期
Erythropoietin in TraumaTraumatic InjuryMedDRA version: 23.1Level: SOCClassification code 10022117Term: Injury, poisoning and procedural complicationsSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsEUCTR2020-003388-24-SIniversity College Dublin2,500